Two independent cohorts of patients with NSCLC on anti-PD-1 therapy verified that H. pylori seropositivity is associated with a lower effectiveness of anti-PD-1 immunotherapy in humans [31]. Here, PDCD1 is linked to non-small cell lung carcinoma.